Topic

UnitedHealthcare (UnitedHealth Group)

A collection of 1322 issues

How to Get Lutathera (Lutetium Lu-177 Dotatate) Covered by UnitedHealthcare in Virginia: Prior Authorization, Appeals & Forms

Quick Answer: Getting Lutathera Covered by UnitedHealthcare in Virginia Lutathera requires prior authorization from UnitedHealthcare OptumRx in Virginia. Your oncologist must submit clinical documentation proving somatostatin receptor positivity, appropriate tumor grading, and progression on octreotide/lanreotide. If denied, you have 180 days for internal appeals, then 120 days to file
5 min read

How to Renew Tysabri (Natalizumab) Coverage with UnitedHealthcare in North Carolina: Evidence Package & Timeline Guide

Answer Box: Renewing Tysabri Coverage with UnitedHealthcare in North Carolina UnitedHealthcare requires annual prior authorization renewal for Tysabri (natalizumab) with specific evidence: recent MRI results, current JCV antibody testing, comprehensive neurologist documentation, and ongoing TOUCH program enrollment. Start renewal 60-90 days before expiration. If denied, North Carolina's Smart
5 min read

Getting Rystiggo (Rozanolixizumab-noli) Covered by UnitedHealthcare in Texas: Coding, Appeals, and Prior Authorization Guide

Answer Box: Fast Track to Rystiggo Coverage UnitedHealthcare requires prior authorization and step therapy for Rystiggo (rozanolixizumab-noli) in Texas. Your fastest path: (1) Gather documentation of AChR/MuSK-positive myasthenia gravis diagnosis with ICD-10 code G70.00 or G70.01, (2) Document failures/intolerances to standard therapies like pyridostigmine and steroids,
6 min read

How to Get Orfadin (nitisinone) Covered by UnitedHealthcare in Ohio: Prior Authorization Guide with Appeals Process

Answer Box: Getting Orfadin Covered by UnitedHealthcare in Ohio UnitedHealthcare requires prior authorization for Orfadin (nitisinone) in Ohio, with automated approval possible within 30 seconds when criteria are met. The fastest path: (1) Confirm HT-1 diagnosis with elevated succinylacetone levels and genetic testing, (2) Submit PA through the UnitedHealthcare Provider
7 min read

How to Get Tavalisse (Fostamatinib) Covered by UnitedHealthcare in Illinois: Complete Guide with Forms and Appeal Strategies

Answer Box: Getting Tavalisse Covered by UnitedHealthcare in Illinois UnitedHealthcare requires prior authorization for Tavalisse (fostamatinib) in Illinois, with strict step therapy requirements including failed corticosteroids and thrombopoietin receptor agonists. Illinois law prohibits step therapy for state-regulated plans as of 2025, but this doesn't apply to self-insured employer
6 min read

Qalsody (Tofersen) Approval with UnitedHealthcare in Michigan: Answers to the Most Common Questions

Answer Box: Getting Qalsody (Tofersen) Covered by UnitedHealthcare in Michigan Yes, UnitedHealthcare covers Qalsody (tofersen) for ALS patients with confirmed SOD1 mutations, but requires prior authorization through OptumRx. Key requirements: SOD1 genetic testing, neurologist prescription, baseline ALSFRS-R score, and no invasive ventilation. If denied, Michigan residents have 127 days to
6 min read

Myths vs. Facts: Getting Busulfex (busulfan injection) Covered by UnitedHealthcare in Georgia

Answer Box: Getting Busulfex Covered by UnitedHealthcare in Georgia Busulfex (busulfan injection) requires prior authorization through UnitedHealthcare/OptumRx for bone marrow transplant conditioning. The fastest path to approval: (1) Submit PA via the UnitedHealthcare Provider Portal with complete clinical documentation including diagnosis, prior therapy failures, and transplant protocol details, (2)
5 min read

How to Get Vanflyta (Quizartinib) Covered by UnitedHealthcare in Ohio: Complete Appeal Guide with Forms and Timelines

Quick Answer: Getting Vanflyta Covered by UnitedHealthcare in Ohio UnitedHealthcare requires prior authorization for Vanflyta (quizartinib) through OptumRx. Most approvals need: (1) documented FLT3-ITD positive AML diagnosis, (2) oncologist prescription, (3) baseline EKG showing safe QTc interval, and (4) treatment plan for induction/consolidation phases. If denied, you have 180
5 min read